According to filings with the U.S. Securities and Exchange Commission, Alzheon is raising up to $49,995,798.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Martin Tolar played…
According to filings with the U.S. Securities and Exchange Commission, Radiance Biopharma is raising up to $30,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Brooks played a…
According to filings with the U.S. Securities and Exchange Commission, Eleanor Health is raising up to $30,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, William McKinney played a…
March 12, 2024 06:15 AM Pacific Daylight Time BOSTON–(BUSINESS WIRE)–CodaMetrix, the leading artificial intelligence (AI) solution for transforming healthcare and revenue cycle management, today announced that it has closed its $40 million Series B funding…
According to filings with the U.S. Securities and Exchange Commission, Alsym Energy is raising up to $78,351,405.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Michael Hannon played a…
According to filings with the U.S. Securities and Exchange Commission, Prime Medicine is raising $161,000,000.00 in new funding. About Prime Medicine: Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying…
According to filings with the U.S. Securities and Exchange Commission, PepGen is raising $80,100,000.00 in new funding. About PepGen: PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in…
According to filings with the U.S. Securities and Exchange Commission, Ocular Therapeutix is raising $325,000,000.00 in new funding. About Ocular Therapeutix: Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of…
According to filings with the U.S. Securities and Exchange Commission, KalVista Pharmaceuticals is raising $160,100,000.00 in new funding. About KalVista Pharmaceuticals: KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and…
According to filings with the U.S. Securities and Exchange Commission, Great Elm Capital is raising $24,000,000.00 in new funding. About Great Elm Capital: Great Elm Capital Corp. is a business development company which specializes in…